Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 18;26(10):1498-1508.
doi: 10.1093/ibd/izaa215.

Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions

Amy C Porter  1 , Jiri Aubrecht  2 , Chandler Birch  1 , Jonathan Braun  3 , Carolyn Cuff  4 , Suryasarathi Dasgupta  2 , Jeremy D Gale  5 , Robert Hinton  6 , Steven C Hoffmann  7 , Gerard Honig  8 , Bryan Linggi  9 , Marco Schito  1 , Niels Vande Casteele  10   11 , John-Michael Sauer  1
Affiliations

Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions

Amy C Porter et al. Inflamm Bowel Dis. .

Abstract

Background: Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn's disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD.

Methods: With support from the Helmsley Charitable Trust, Critical Path Institute formed the Crohn's Disease Biomarkers preconsortium (CDBpC) with members from the pharmaceutical industry, academia, and nonprofit organizations to evaluate the CD biomarker landscape. Biomarkers were evaluated based on biological relevance, availability of biomarker assays, and clinical validation data.

Results: The CDBpC identified the most critical need as pharmacodynamic/response biomarkers to monitor disease activity in response to therapeutic intervention. Fecal calprotectin (FC) and serum C-reactive protein (CRP) were identified as biomarkers ready for the regulatory qualification process. A number of exploratory biomarkers and potential panels of these biomarkers was also identified for additional development. Given the different factors involved in CD and disease progression, a combination of biomarkers, including inflammatory, tissue injury, genetic, and microbiome-associated biomarkers, will likely have the most utility.

Conclusions: The primary focus of the Inflammatory Bowel Disease Regulatory Science Consortium will be development of exploratory biomarkers and the qualification of FC and CRP for IBD. The Inflammatory Bowel Disease Regulatory Science Consortium, focused on tools to support IBD drug development, will operate in the precompetitive space to share data, biological samples for biomarker testing, and assay information for novel biomarkers.

Keywords: Crohn’s disease; biomarker; biomarker qualification; inflammatory bowel disease; regulatory science; ulcerative colitis.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
CD biomarker landscape assessment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Caprilli R. Why does Crohn’s disease usually occur in terminal ileum? J. Crohns Colitis. 2008;2:352–356. - PubMed
    1. NIDDK. Crohn’s Disease. 2017. Accessed May 28, 2020. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-d....
    1. Crohn’s and Colitis Foundation. About Crohn’s Disease and Ulcerative Colitis. 2018. Accessed April 17, 2020. https://www.crohnscolitisfoundation.org/sites/default/files/legacy/asset....
    1. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. - PMC - PubMed
    1. Dahlhamer JM, Zammitti EP, Ward BW, et al. . Prevalence of inflammatory bowel disease among adults aged ≥18 years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166–1169. - PubMed

Publication types